AVD American Vanguard Corporation - Fundamental Analysis
BEARISH
Sign in to save
Save this symbol to a watchlist or track a position.
AVD Stock | Fundamental Analysis & Investment Insights
NYSE
Basic Materials
Agricultural Inputs
Current Price
Live
$4.91
52W High
$6.33
52W Low
$3.28
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 24, 2026
Market cap
$139.78M
P/E
N/A
ROE
-40.8%
Profit margin
-21.1%
Debt/Equity
0.91
Dividend yield
N/A
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
85%
Analysis Accuracy
The Advanced Deterministic Scorecard reveals a critically weak financial health with a Piotroski F-Score of just 1/9, indicating severe operational and profitability concerns. Despite a low Price/Book of 0.65 and Price/Sales of 0.26 suggesting potential value, the company is unprofitable with a -21.15% profit margin and -40.84% ROE, undermining valuation appeal. Earnings volatility is extreme, with recent quarters missing estimates by over -400% on average, and insider selling adds to negative sentiment. While short-term price momentum is positive, the fundamental deterioration and lack of analyst coverage signal high risk.
Key Strengths
Low valuation multiples: Price/Book of 0.65 and Price/Sales of 0.26 suggest potential undervaluation relative to book and revenue.
Current Ratio of 1.77 indicates short-term liquidity is manageable despite broader financial stress.
Gross Margin of 24.11% shows core operations retain pricing power or cost control at production level.
Recent short-term price momentum is strong: +31.6% over 6M and +23.4% over 1M.
Debt/Equity of 0.91, while elevated, is within range for the sector (avg 0.61), suggesting leverage is not extreme by industry standards.
Key Risks
Critically low Piotroski F-Score of 1/9 signals severe financial distress and poor fundamental health.
Negative profitability across all metrics: -21.15% profit margin, -4.37% operating margin, and -40.84% ROE indicate systemic losses.
Extreme earnings volatility and consistent misses: last 4 quarters averaged -231.11% earnings surprise, with multiple misses exceeding -400%.
Insider selling observed: 1 sale transaction worth $0.03M with no buys, signaling lack of confidence from insiders.
No analyst coverage or target price, reflecting low market confidence and limited external validation of valuation.
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
27
Weak
55
30
25
15
10
AI Verdict
High-risk, fundamentally weak company with misleadingly low valuation metrics overshadowed by severe profitability and earnings quality issues.
Key drivers: Piotroski F-Score of 1/9, Negative ROE and profit margin, Extreme earnings surprise volatility, Insider selling, No analyst coverage
Confidence
88%
Value
55/100
Ref P/E, PEG, Graham Number
Positives
- Low Price/Book (0.65)
- Low Price/Sales (0.26)
- Forward P/E of 12.59 below sector average
Watchpoints
- No Graham Number or Intrinsic Value available
- Unprofitability undermines valuation multiples
Future
30/100
Ref Growth rates
Positives
- Revenue growth YoY of 0.90% shows minimal top-line stability
- Forward P/E implies some growth expectations
Watchpoints
- No earnings growth data (YoY or Q/Q)
- Extreme negative earnings surprises forecast instability
- No analyst targets to support forward outlook
Past
25/100
Ref Historical trends
Positives
- Some past quarters beat estimates (e.g., +75% in 2023-03-13)
- Historical ROE and margins were positive pre-2023
Watchpoints
- Consistent earnings misses since 2023
- Profitability collapsed: from positive to deeply negative margins
- 5Y price return of -72.7% reflects long-term underperformance
Health
15/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Current Ratio of 1.77 supports short-term liquidity
- Quick Ratio of 0.86, though low, is not critical
Watchpoints
- Piotroski F-Score of 1/9 indicates severe financial weakness
- ROA of -1.62% shows assets are destroying value
- ROE of -40.84% reflects equity erosion
Dividend
10/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- Dividend Strength of 0/100
- No dividend yield or payout history
- Payout ratio of 0% due to no dividend
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$4.91
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for AVD and closest competitors.
Updated 2026-01-23
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
AVD
American Vanguard Corporation
Primary
|
-72.7% | -78.1% | -12.5% | +31.6% | +23.4% | +14.2% |
|
AMTX
Aemetis, Inc.
Peer
|
-88.1% | -17.0% | +44.0% | +6.0% | +50.7% | +63.6% |
|
ACNT
Ascent Industries Co.
Peer
|
+29.2% | +48.5% | +3.6% | +1.1% | -27.8% | -3.5% |
|
BIOX
Bioceres Crop Solutions Corp.
Peer
|
-85.0% | -90.1% | -82.5% | -68.0% | -11.8% | -7.0% |
|
BON
Bon Natural Life Limited
Peer
|
-99.9% | -99.4% | -95.2% | +23.2% | +3.0% | +1.2% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
12.59
PEG Ratio
N/A
P/B Ratio
0.65
P/S Ratio
0.26
EV/Revenue
0.61
EV/EBITDA
220.12
Market Cap
$139.78M
Profitability
Profit margins and return metrics
Profit Margin
-21.15%
Operating Margin
-4.37%
Gross Margin
24.11%
ROE
-40.84%
ROA
-1.62%
Growth
Revenue and earnings growth rates
Revenue Growth
+0.9%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.91
Moderate
Current Ratio
1.77
Good
Quick Ratio
0.86
Poor
Cash/Share
$0.59
Quarterly Earnings History
EPS performance vs analyst estimates
2026-03-11
$N/A
2025-11-10
$-0.43
-437.5% surprise
2025-07-31
$-0.03
+72.7% surprise
2025-06-06
$-0.3
-328.6% surprise
Basic Materials Sector Comparison
Comparing AVD against 41 companies in the Basic Materials sector
(1 bullish, 21 neutral, 19 bearish)
Return on Equity (ROE)
-40.84%
This Stock
vs
0.39%
Sector Avg
-10449.7%
(Below Avg)
Profit Margin
-21.15%
This Stock
vs
-2.52%
Sector Avg
+738.1%
(Superior)
Debt to Equity
0.91
This Stock
vs
0.61
Sector Avg
+49.9%
(Higher)
Revenue Growth
0.9%
This Stock
vs
14.81%
Sector Avg
-93.9%
(Slower)
Current Ratio
1.77
This Stock
vs
2.28
Sector Avg
-22.5%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
AVD
American Vanguard Corporation
|
BEARISH | $139.78M | - | -40.8% | -21.1% | $4.91 | |
|
AMTX
Aemetis, Inc.
|
BEARISH | $151.6M | - | -% | -43.6% | $2.29 | |
|
ACNT
Ascent Industries Co.
|
BEARISH | $119.97M | - | -6.2% | 1.2% | $12.79 | |
|
BIOX
Bioceres Crop Solutions Corp.
|
BEARISH | $76.17M | - | -18.9% | -17.7% | $1.2 | |
|
BON
Bon Natural Life Limited
|
BEARISH | $17.29M | 0.08 | 1.2% | 2.7% | $1.7 |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2025-09-04 | EILERS PETER | Officer | Sale | 6,000 | $32,100 |
| 2025-08-07 | BASKIN SCOTT D | Director | Stock Award | 8,810 | - |
| 2025-08-07 | GUNTER EMER OBROIN | Director | Stock Award | 8,810 | - |
| 2025-08-07 | ANGELINI MARISOL | Director | Stock Award | 17,621 | - |
| 2025-08-07 | ROSENBLOOM KEITH M | Director | Stock Award | 17,621 | - |
| 2025-08-07 | GOTTSCHALK PATRICK EDWARD | Director | Stock Award | 17,621 | - |
| 2025-08-07 | BASSETT MARK R | Director | Stock Award | 17,621 | - |
| 2025-08-07 | MACICEK STEVEN D | Director | Stock Award | 17,621 | - |
| 2025-08-07 | TIU DE MINO CARMEN | Director | Stock Award | 17,621 | - |
Insider transactions can signal confidence or concerns about company prospects
Past News Coverage
Recent headlines mentioning AVD from our newsroom.
Newest → oldest
No matching news yet.